Oncotarget is an open-access medical journal which is peer-reviewed and covers all fields of oncology as well as issues related to microbiology, immunology, aging, and chromosomes. The Journal has over hundreds of board members and editors who are the specialist in the fields that the journal covers. It was founded in 2010, and it has published six volumes and over 300 issues since then. It is now on the 8th volume and issues 47 to 50 were processed by National Library of medicine. The journal is among the first to submit an entire issue of publication to PubMed. It is published in Impact Journals with weekly publications. Its editors-in-chief are Mikhail Blagosklonny and Andrei Gudkov who work at Rosewell park cancer institute. The journal works with high profile scientific directories in order to make scientific results and research available to all researchers working in the medical field, medical students and the general public. The journal has been publishing two issues weekly; on Tuesdays and Fridays in order to provide information and news immediately it comes out as well as cover all aspects of the medical field widely. In 2013, four of the board members were awarded the Breakthrough Prize in appreciation of the excellent work the journal is doing worldwide.

The Journal nurtures the application of basic and clinical science to fight diseases. It has largely contributed to the removal of borders between researchers and specialists, therefore, giving them a chance to learn from each other and improve the medical research field. This has greatly contributed to the progress of research institutes as well as individuals. The organization’s main objective is to create a world without diseases especially cancer. Therefore, it accepts research papers from all over the world.

According to MEDLINE, the journal plays a critical role in the medical field by publishing basic medical research papers while following ethics as well as good editorial practices. This is because it publishes each paper under the recommendations of the Committee on Publication Ethics and gives each paper a Direct Object Identifier (DOI). The journal accepts papers from researchers, edits them then publishes the papers and releases them under PubMed in their permanent form.

Facebook: https://www.facebook.com/Oncotarget/

Impact Journals founded Oncotarget in 2010, where many other types of journals can be found online. The editors-in-chief are Mikhail Blagosklonny and Andrei V. Gudkov (Roswell Park Cancer Institute). Oncotarget is an online magazine where papers can be published for the media. The online magazine has peer-review functions for all articles. The submission process is entirely online. Oncotarget publishes papers on neuroscience, endocrinology, cardiology, metabolism, cell biology, pharmacology, and oncology, which is the study of cancer. You can find Oncotarget archives by clicking on the special collections link. Oncotarget’s impact factor is listed on the front page of the website oncotarget.com. Defined, the impact factor is the frequency a journal is cited during one full calendar year. The Oncotarget Impact Factor for 2016 is 30,241 cities and the factor itself is 5.168.

You can find Impact Journal’s Oncotarget on social media using their Facebook page or going to the Impact Journals’ website. Oncotarget has published a study that found e-cigarettes could cause damage to gum tissue. E-cigarettes cause inflammation in general but flavored cigarettes are much worse. Apparently, this study says that using either form of cigarette, which can cause gum injuries, what can damage DNA. There is a link between smoking and teeth losing their cohesion, which requires more fillings. E-cig aerosols contribute further to tooth decay rather than conventional cigarette use. Teeth can rot with age and e-cigarette use.

Their other article is “MET amplification as a potential therapeutic target in gastric cancer.” MET refers to metabolic equivalent. Gastric cancer is the third leading cause of death in men, and fifth for women, in the world. Survival rates are 1 year for individuals receiving conventional therapy. Trastuzumab is an antibody targeted to the HER2 gene. There is a higher survival rate because of this treatment. In the study titled above, 266 patients were studied. 68.8% of patients were male. MET mRNA managed to inhibit the growth of cancer cells somewhat. This study was done in Japan between 1996 and 2006. Cell growth was inhibited in this study.

Seattle Genetics is Washington’s largest biotech company, and is slowly but surely moving to the big pharma league. It is valued at almost $10 billion, and has 900 employees and plans to increase the number to 1,100. The company was founded in 1998 by Clay Siegall, who is currently its CEO. It has done extensive research on oncology and cancer treatment, and has been studying human antibodies to find out how they can be used to fight cancer.

 

Seattle Genetics has 11 cancer drugs in the works, 4 of which are likely to be released into the market soon. These 4 are in the final stages of testing. One of these is Adcetris, which is being tested for use as a front-line drug in the treatment of Hodgkin lymphoma, a type of cancer which affects the lymphatic system. Adcetris has already been approved by the FDA for use by patients whose first or second drugs are not effective. Projected annual sales from it are $1 billion if it is approved as a front-line treatment. Seattle Genetics is also doing research on the possibility of using Adcetris in combination with Opdivo, a type of checkpoint inhibitor used in immunotherapy. The other 3 drugs are for the treatment of bladder cancer, breast cancer, and acute myeloid leukemia. The approval of these drugs will be a huge step in the treatment of these types of cancer.

 

About Clay Siegall

Clay Siegall has extensive experience in the biopharmaceutical industry and is very passionate about the fight against cancer. Under his leadership, Seattle Genetics has played a great role in advancements in the treatment against cancer. His secret to success is diversification. Unlike other biotech companies which focus all their energies on one or two drugs and end up crumbling if they are not approved, he does extensive research on different types of cancer and the existing treatment options. This enables him to produce more effective drugs. He also learns from industry authorities and tries to emulate some of their business models in Seattle Genetics. This is how Clay Siegall ensures that Seattle Genetics remains relevant in the industry.

 

Conclusion

Clay Siegall is committed to the fight against cancer, and this is what gives him the motivation to keep researching and producing cancer drugs. He acknowledges that it is not easy but nothing will stop him. Thanks to his visionary leadership, Seattle Genetics has made huge strides in the treatment of cancer and continues to forge on despite the numerous challenges in the industry.